- Report
- September 2025
Global
From €4233EUR$4,799USD£3,719GBP
- Report
- August 2025
- 195 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Drug Pipelines
- July 2025
- 280 Pages
Global
From €2117EUR$2,400USD£1,860GBP
€2646EUR$3,000USD£2,325GBP
- Report
- December 2025
- 406 Pages
Global
From €6170EUR$6,995USD£5,420GBP
- Report
- September 2025
- 325 Pages
Global
From €4233EUR$4,799USD£3,719GBP
- Report
- May 2025
- 483 Pages
Global
From €5125EUR$6,013USD£4,350GBP
- Report
- June 2025
- 456 Pages
Global
From €4366EUR$4,950USD£3,836GBP
- Report
- March 2025
Global
From €4322EUR$4,900USD£3,797GBP
- Report
- September 2025
- 147 Pages
Global
From €2249EUR$2,549USD£1,975GBP
€2645EUR$2,999USD£2,324GBP
- Report
- June 2025
- 135 Pages
Global
From €2249EUR$2,549USD£1,975GBP
€2645EUR$2,999USD£2,324GBP
- Report
- June 2025
- 150 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- June 2025
- 135 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- March 2025
- 120 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- August 2025
- 181 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 196 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 198 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- November 2025
- 182 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 195 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP
- Report
- October 2025
- 183 Pages
Global
From €3127EUR$3,545USD£2,747GBP
€3475EUR$3,939USD£3,052GBP

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body.
The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more